Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Clinical Investigation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 15841215PMCID PMC1070635
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractions Published, JLR Papers in Press, October 16, 2004. DOI 10.1194/jlr.M400108-JLR200

  2005cited by this paper
• Regulation of Hepatic Apolipoprotein B-lipoprotein Assembly and Secretion by the Availability of Fatty Acids

  2004cited by this paper
• Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice.

  2004cited by this paper
• Association of the APOLIPOPROTEIN A1/C3/A4/A5 Gene Cluster With Triglyceride Levels and LDL Particle Size in Familial Combined Hyperlipidemia

  2004cited by this paper
• Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.

  2004cited by this paper
• One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

  2004cited by this paper
• The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo.

  2004cited by this paper
• Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.

  2004cited by this paper
• Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

  2004cited by this paper
• Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients

  2004cited by this paper
• Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

  2004cited by this paper
• Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation.

  2003cited by this paper
• Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement.

  2003cited by this paper
• Activation of Peroxisome Proliferator–Activated Receptor Gamma and Retinoid X Receptor Results in Net Depletion of Cellular Cholesteryl Esters in Macrophages Exposed to Oxidized Lipoproteins

  2003cited by this paper
• PPAR(gamma) and glucose homeostasis.

  2003cited by this paper
• Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor α Activators*

  2003cited by this paper
• Adiponectin: Systemic contributor to insulin sensitivity

  2003cited by this paper
• Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.

  2003cited by this paper
• Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.

  2003cited by this paper
• Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma.

  2003cited by this paper
• CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-γ

  2003cited by this paper
• Measurement of the serum lipoprotein lipase concentration is useful for studying triglyceride metabolism: Comparison with postheparin plasma.

  2003cited by this paper
• Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass*

  2003cited by this paper
• Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes.

  2003cited by this paper
• Conditional Disruption of the Peroxisome Proliferator-Activated Receptor γ Gene in Mice Results in Lowered Expression of ABCA1, ABCG1, and apoE in Macrophages and Reduced Cholesterol Efflux

  2002cited by this paper
• Addressing the insulin resistance syndrome: a role for the thiazolidinediones.

  2002cited by this paper
• Differences in Lipid Profiles of Patients Given Rosiglitazone Followed by Pioglitazone

  2002cited by this paper
• The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

  2002cited by this paper
• Orphan Nuclear Hormone Receptor Rev-erbα Regulates the Human Apolipoprotein CIII Promoter*

  2002cited by this paper
• Ameliorated Hepatic Insulin Resistance Is Associated with Normalization of Microsomal Triglyceride Transfer Protein Expression and Reduction in Very Low Density Lipoprotein Assembly and Secretion in the Fructose-fed Hamster*

  2002cited by this paper
• Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

  2002cited by this paper
• Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.

  2002cited by this paper
• Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus.

  2002cited by this paper
• Hormone-sensitive Lipase Deficiency in Mice Changes the Plasma Lipid Profile by Affecting the Tissue-specific Expression Pattern of Lipoprotein Lipase in Adipose Tissue and Muscle*

  2002cited by this paper
• Dyslipidemia of the metabolic syndrome

  2002cited by this paper
• Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

  2002cited by this paper
• Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins*

  2002cited by this paper
• Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.

  2002cited by this paper
• Increased hepatic VLDL secretion, lipogenesis, and SREBP-1 expression in the corpulent JCR:LA-cp rat.

  2001cited by this paper
• An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing

  2001cited by this paper
• Transcriptional Regulation of Apolipoprotein C-III Gene Expression by the Orphan Nuclear Receptor RORα*

  2001cited by this paper
• Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

  2001cited by this paper
• Peroxisome proliferator-activated receptor gamma and metabolic disease.

  2001cited by this paper
• Pre-heparin plasma lipoprotein lipase mass: correlation with intra-abdominal visceral fat accumulation.

  2001cited by this paper
• Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.

  2000cited by this paper
• Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

  2000cited by this paper
• Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.

  2000cited by this paper
• Insulin resistance and cardiovascular disease.

  2000cited by this paper
• Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets.

  2000cited by this paper
• Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase.

  2000cited by this paper
• Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance

  2000cited by this paper
• Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice.

  2000cited by this paper
• The Insulin Resistance Syndrome: Impact on Lipoprotein Metabolism and Atherothrombosis

  2000cited by this paper
• The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum.

  1999cited by this paper
• Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes.

  1999cited by this paper
• A Review of Metabolic and Cardiovascular Effects of Oral Antidiabetic Agents: Beyond Glucose-Level Lowering

  1999cited by this paper
• Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance.

  1999cited by this paper
• Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach.

  1998cited by this paper
• Mechanism of action of fibrates on lipid and lipoprotein metabolism.

  1998cited by this paper
• Life without white fat: a transgenic mouse.

  1998cited by this paper
• Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus

  1998cited by this paper
• Role of human liver lipogenesis and reesterification in triglycerides secretion and in FFA reesterification.

  1998cited by this paper
• Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM

  1997cited by this paper
• Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

  1997cited by this paper
• Sandwich immunoassay for measurement of human hepatic lipase.

  1996cited by this paper
• Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

  1996cited by this paper
• Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man.

  1996cited by this paper
• Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes.

  1996cited by this paper
• PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene.

  1996cited by this paper
• Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM

  1995cited by this paper
• Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.

  1995cited by this paper
• Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia.

  1995cited by this paper
• Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.

  1995cited by this paper
• Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia.

  1994cited by this paper
• Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion.

  1994cited by this paper
• Obese Zucker (fa/fa) rats are resistant to insulin's inhibitory effect on hepatic apo B secretion.

  1994cited by this paper
• Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.

  1994cited by this paper
• Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

  1993cited by this paper
• Effects of Acute Hyperinsulinemia on VLDL Triglyceride and VLDL ApoB Production in Normal Weight and Obese Individuals

  1993cited by this paper
• Human lipoprotein lipase: relationship of activity, heparin affinity, and conformation as studied with monoclonal antibodies.

  1992cited by this paper
• Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.

  1992cited by this paper
• George Lyman Duff Memorial Lecture. Atherogenesis in diabetes.

  1992cited by this paper
• Lipoprotein Physiology in Nondiabetic and Diabetic States: Relationship to Atherogenesis

  1991cited by this paper
• Measurement of de novo hepatic lipogenesis in humans using stable isotopes.

  1991cited by this paper
• Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.

  1990cited by this paper
• Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration.

  1989cited by this paper
• Interrelationships Among Insulin's Antilipolytic and Glucoregulatory Effects and Plasma Triglycerides in Nondiabetic and Diabetic Patients With Endogenous Hypertriglyceridemia

  1988cited by this paper
• Role of insulin in regulation of lipoprotein metabolism in diabetes.

  1988cited by this paper
• Very low density lipoprotein metabolism in diabetes mellitus.

  1987cited by this paper
• Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

  1986cited by this paper
• Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss.

  1985cited by this paper
• Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease.

  1985cited by this paper
• Very-Low-Density Lipoprotein Triglyceride Metabolism in Non-insulin-dependent Diabetes Mellitus: Relationship to Plasma Insulin and Free Fatty Acids

  1983cited by this paper
• Effect of somatostatin-induced suppression of postprandial insulin response upon the hypertriglyceridemia associated with a high carbohydrate diet.

  1982cited by this paper
• Dissociation of apoprotein B and triglyceride production in very-low-density lipoproteins.

  1980cited by this paper
• Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects.

  1980cited by this paper
• Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.

  1972cited by this paper
• Splanchnic metabolism of free fatty acids and production of triglycerides of very low density lipoproteins in normotriglyceridemic and hypertriglyceridemic humans.

  1970cited by this paper
• Diabetic lipemia. A form of acquired fat-induced lipemia.

  1967cited by this paper

• Exercise-Induced Muscle–Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging

  2025cites this paper
• Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease.

  2025cites this paper
• Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome

  2025cites this paper
• A combined network pharmacology and experimental approach to investigate the mechanisms of curcumin on diabetes through the adipocytokine signaling pathway

  2025cites this paper
• Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial

  2024cites this paper
• Associations of Phthalate Exposure With Adiposity and Metabolic Syndrome in US Adolescents and Adults, NHANES 2013 to 2018

  2024cites this paper
• TM6SF2 Determines Both the Degree of Lipidation and the Number of VLDL Particles Secreted by the Liver

  2023cites this paper
• Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma

  2023cites this paper
• Peroxisome proliferator-activated receptors as targets to treat metabolic diseases: Focus on the adipose tissue, liver, and pancreas

  2023cites this paper
• Effects of Administration of Recombinant Human Lecithin-Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans

  2023cites this paper
• Pioglitazone in diabetic kidney disease: forgotten but not gone

  2022cites this paper
• Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis

  2021cites this paper
• Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

  2021cites this paper
• Unravelling Lipoprotein Metabolism with Stable Isotopes: Tracing the Flow.

  2021cites this paper
• The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD

  2021cites this paper
• Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study

  2020cites this paper
• Uncovering the role of apolipoprotein C-III in insulin resistance.

  2020cites this paper
• The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans

  2020cites this paper
• Co-administration of vitamin E and atorvastatin improves insulin sensitivity via peroxisome proliferator-activated receptor γ in hyperlipidemic type 2 diabetic patients: a randomized double-blinded clinical trial

  2020cites this paper
• Study the efficacy of herbal formulation Niśāmalakī in animal model of polycystic ovarian disease syndrome

  2019cites this paper
• Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism

  2019cites this paper
• Apolipoprotein CIII and diabetes. Is there a link?

  2019cites this paper
• Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD

  2019cites this paper
• Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?

  2019cites this paper
• Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

  2018cites this paper
• PPAR&ggr; deacetylation dissociates thiazolidinedione’s metabolic benefits from its adverse effects

  2018cites this paper
• Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases.

  2018cites this paper
• Study of the effect of the herbal composition SR2004 on hemoglobin A1c, fasting blood glucose, and lipids in patients with type 2 diabetes mellitus

  2018cites this paper
• The Effect of Morinda citrifolia L. Fruit Juice on the Blood Sugar Level and Other Serum Parameters in Patients with Diabetes Type 2

  2018cites this paper
• Pathophysiology of Diabetic Dyslipidemia

  2018cites this paper
• Effects of high fructose intake on the development of hypertension in the spontaneously hypertensive rats: the role of AT1R/gp91PHOX signaling in the rostral ventrolateral medulla.

  2017cites this paper
• The metabolism of lipoprotein (a): an ever-evolving story

  2017cites this paper
• The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.

  2017cites this paper
• Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function.

  2017cites this paper
• ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen

  2017cites this paper
• PPAR&ggr; Agonists Attenuate Trigeminal Neuropathic Pain

  2017cites this paper
• A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels

  2017cites this paper
• Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.

  2017cites this paper
• Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E[S]

  2017cites this paper
• Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes

  2017cites this paper
• Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease

  2017cites this paper
• Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

  2017cites this paper
• Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

  2017cites this paper
• Comparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease.

  2016cites this paper
• Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans

  2016cites this paper
• Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats

  2016cites this paper
• Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Increases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein

  2016cites this paper
• Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy.

  2016cites this paper
• Targeting ApoC-III to Reduce Coronary Disease Risk

  2016cites this paper
• Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1

  2016cites this paper
• Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery.

  2015cites this paper
• Targeting fatty acid metabolism to improve glucose metabolism

  2015cites this paper
• Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study

  2015cites this paper
• Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor γ/δ agonists.

  2015cites this paper
• Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.

  2015cites this paper
• Apolipoprotein C-III: From Pathophysiology to Pharmacology.

  2015cites this paper
• ATTENUATING TRIGEMINAL NEUROPATHIC PAIN BY REPURPOSING PIOGLITAZONE AND D-CYCLOSERINE IN THE NOVEL TRIGEMINAL INFLAMMATORY COMPRESSION MOUSE MODEL

  2014cites this paper
• Phytotherapy in diabetes: Review on potential mechanistic perspectives.

  2014cites this paper
• Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice

  2014cites this paper
• The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus

  2013cites this paper
• Novel benefits of peroxisome proliferator-activated receptors on cardiovascular risk

  2013cites this paper
• Effects of Pioglitazone on Insulin Sensitivity and Serum Lipids in Obese Cats

  2013cites this paper
• Herpesvirus-associated Ubiquitin-specific Protease (HAUSP) Modulates Peroxisome Proliferator-activated Receptor γ (PPARγ) Stability through Its Deubiquitinating Activity*

  2013cites this paper
• Influence of pioglitazone on experimental heart failure and hyperlipidemia in rats

  2012cites this paper
• Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production

  2012cites this paper
• Pioglitazone

  2012cites this paper
• Endocrine fibroblast growth factors 15/19 and 21: from feast to famine.

  2012cites this paper
• Antidiabetic Effect of Morinda citrifolia (Noni) Fermented by Cheonggukjang in KK-Ay Diabetic Mice

  2012cites this paper
• Regulation of chylomicron production in humans.

  2012cites this paper
• Role of adipose and hepatic atypical protein kinase C lambda (PKCλ) in the development of obesity and glucose intolerance

  2012cites this paper
• PPAR agonists for the treatment of cardiovascular disease in patients with diabetes

  2012cites this paper
• Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit.

  2011cites this paper
• Gut-liver interaction in triglyceride-rich lipoprotein metabolism.

  2011cites this paper
• Apolipoprotein CIII: 42 years old and even more interesting.

  2011cites this paper
• Dynamic Changes of Adiponectin and S100A8 Levels by the Selective Peroxisome Proliferator–Activated Receptor-&ggr; Agonist Rivoglitazone

  2011cites this paper
• Differential Effects of Rosiglitazone and Metformin on Postprandial Lipemia in Patients With HIV-Lipodystrophy

  2011cites this paper
• Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

  2011cites this paper
• Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ.

  2011cites this paper
• Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.

  2011cites this paper
• Peroxisome proliferator-activated receptors and hepatitis C virus

  2011cites this paper
• Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells

  2010cites this paper
• New treatments for chronic hepatitis C

  2010cites this paper
• Pioglitazone improves virological response to peginterferon α‐2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance

  2010cites this paper
• Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity.

  2010cites this paper
• A State Space Transformation Can Yield Identifiable Models for Tracer Kinetic Studies with Enrichment Data

  2010cites this paper
• Pioglitazone decreases plasma angiotensin II concentration in type 2 diabetes.

  2010cites this paper
• Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus.

  2010cites this paper
• Withdrawal of pioglitazone in patients with type 2 diabetes mellitus

  2010cites this paper
• Pioglitazone in the treatment of NASH: the role of adiponectin

  2010cites this paper
• Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus

  2010cites this paper
• Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes.

  2010cites this paper
• Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14).

  2009cites this paper
• The role of pioglitazone in modifying the atherogenic lipoprotein profile

  2009cites this paper
• Cleavage of Protein Kinase D After Acute Hypoinsulinemia Prevents Excessive Lipoprotein Lipase–Mediated Cardiac Triglyceride Accumulation

  2009cites this paper
• Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids

  2009cites this paper
• Relationship between total and high molecular weight adiponectin levels and plasma nonesterified fatty acid tolerance during enhanced intravascular triacylglycerol lipolysis in men.

  2009cites this paper
• Beneficial Effects of Sarpogrelate Hydrochloride, a 5-ht2a Receptor Antagonist, Supplemented with Pioglitazone on Diabetic Model Mice

  2009cites this paper
• Pathogenesis and Management of the Dyslipidemia of the Metabolic Syndrome

  2009cites this paper
• Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients.

  2009cites this paper
• Thiazolidinediones and the liver in humans

  2009cites this paper